People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NextPoint Therapeutics, Inc. | — | Biotechnology | Series C | $122.5M | $443.6M | 2024 |
| Simcha Therapeutics Holding Company, LLC | — | Biotechnology | Series B | $68.1M | $33.7M | 2025 |
Axel Hoos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Axel Hoos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ansbert Gadicke | 1 | 7 |
| R. Jacob Vogelstein | 1 | 6 |
| Paulina Hill | 1 | 5 |
| Terry Rosen | 1 | 4 |
| Detlev Biniszkiewicz | 1 | 4 |
| Matthew Roden | 1 | 3 |
| Aaron Ring | 1 | 3 |
| Jake Bauer | 1 | 2 |
| Joseph Catino | 1 | 2 |
| Rakhshita Dhar | 1 | 2 |
| Beatrice McQueen | 1 | 2 |
| Paul Conrad | 1 | 1 |
| Yiming Li | 1 | 1 |
| Sanuj Ravindran | 1 | 1 |
| Simeon H. George | 1 | 1 |
| Terry L. Rosen | 1 | 1 |
| Lennart H. Lee | 1 | 1 |
| Gu Cuiping | 1 | 1 |
| Beatrice L. McQueen | 1 | 1 |
| Richard Soll | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.